Continuous Bioprocessing Market Size was valued at USD 255.9 Mn in 2023 and is predicted to reach USD 1,067.8 Mn by 2031 at a 19.72% CAGR during the forecast period for 2024-2031.
Continuous bioprocessing is a technology utilized in the production of biopharmaceuticals, wherein manufacturing operations are interconnected seamlessly with minimal hold volume. Several factors contribute to the expansion of this market, including escalating demand for biopharmaceuticals, advancements in continuous bioprocessing technology, ongoing product launches, and global initiatives promoting biopharmaceutical adoption.
The transition towards the bioprocess industry, coupled with burgeoning opportunities in developing nations and a preference for personalized medicine, is expected to fuel significant growth. Moreover, increased government funding for research and development activities further drives market expansion. However, biopharmaceutical companies are also devising strategies to address current and potential future pandemics and mitigate supply shortages, contributing to the rising demand for continuous bioprocessing, particularly amidst the challenges posed by the COVID-19 pandemic.
Competitive Landscape
Some of the Major Key Players in the Continuous Bioprocessing Market are
- 3M
- Bio-Rad Laboratories, Inc.
- Thermo Fisher Scientific, Inc.
- Merck KGaA
- Sartorius AG
- Danaher Corporation
- Corning Incorporated
- Repligen Corporation
- Eppendorf AG
- Entegris, Inc.
- Meissner Filtration Products Inc.
- Kuhner AG
- OmniBRx Biotechnologies Pvt Ltd.
- Bionet
- Solesis Medical
- Other Prominent Players
Market Segmentation:
The continuous bioprocessing market is divided on the basis of product, process, application, and end users. On the basis of product, the global continuous bioprocessing market is segmented into chromatography systems & consumables, filtration systems & devices, bioreactors, cell culture media & reagents, and others. Based on the process, the continuous bioprocessing market is categorized as downstream bioprocess and upstream bioprocess. By application, the market is bifurcated into monoclonal antibodies, vaccines, cell & gene therapy, and other applications. By end users, the continuous bioprocessing market is divided into pharmaceutical & biotechnology companies, academic & research institutes, and contract research organizations.
The Vaccine Segment Holds a Significant Share in the Continuous Bioprocessing Market.
The rising demand for vaccines, especially in response to emerging infectious diseases and pandemics, has spurred interest in continuous bioprocessing for vaccine production. Continuous bioprocessing offers several advantages, including enhanced productivity, reduced manufacturing timelines, and flexibility in response to demand fluctuations. It provides a rapid and scalable manufacturing platform crucial for addressing emerging infectious diseases.
The Upstream Bioprocessing Segment is Witnessing Rapid Growth.
The upstream bioprocessing segment is witnessing rapid growth within the global Continuous Bioprocessing market. This growth reflects an increasing focus on optimizing early-stage biopharmaceutical production. Upstream bioprocessing involves cell cultivation and biomolecule production through techniques such as cell culture and fermentation.
The North America Continuous Bioprocessing Market Holds a Significant Revenue Share.
In terms of regional markets, North America holds a significant revenue share in the continuous bioprocessing market. This is attributed to factors such as the use of bioethanol as an alternative fuel, the presence of major players in the biopharmaceutical industry, and the expanding biologics and biosimilar market. The Asia Pacific regional market is anticipated to experience substantial growth driven by elements such as the expansion of the biopharmaceutical industry, increased life sciences research activities, rising investments by pharmaceutical and biotechnology companies, and the growing market for (CMOs).
Recent Developments:
- March 2021- The (USP) and Plow Corp. joined forces to establish a new laboratory dedicated to developing test methods and standards for continuous manufacturing. This facility prioritizes activities such as product development, technology transfer, and drug application filings, all with the aim of promoting broader adoption of continuous manufacturing among generic drugs and other pharmaceutical manufacturers.
Continuous Bioprocessing Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 255.9 Mn |
|
Revenue Forecast In 2031 |
USD 1,067.8 Mn |
|
Growth Rate CAGR |
CAGR of 19.72% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product, By Process, By Application, By End-user and By Region |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
3M, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., Merck KGaA, Sartorius AG, Danaher Corporation, Corning Incorporated, Repligen Corporation, Eppendorf AG, Entegris, Inc., Meissner Filtration Products Inc., Kuhner AG, OmniBRx Biotechnologies Pvt Ltd., Bionet and Solesis |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
